Related Experiment Video
Updated: Feb 20, 2026

Following in Real Time the Impact of Pneumococcal Virulence Factors in an Acute Mouse Pneumonia Model Using Bioluminescent Bacteria
Published on: February 23, 2014
Community-acquired pneumonia in children - a changing spectrum of disease
David M le Roux1,2, Heather J Zar3
15th Floor ICH Building Red Cross War Memorial Children's Hospital, Klipfontein Road Cape Town, 7700, South Africa. Dave.leRoux@uct.ac.za.
Insights
Childhood pneumonia deaths have decreased due to vaccines, but co-infections and viral causes are rising. Improved access to prevention and management strategies is crucial, especially in low-income nations.
Area of Science:
- Pediatrics
- Infectious Diseases
- Public Health
Background:
- Pneumonia is the leading cause of mortality in children globally outside the neonatal period.
- Significant progress has been made in reducing childhood pneumonia incidence and mortality over the past two decades.
Purpose of the Study:
- To review the impact of conjugate vaccines on childhood pneumonia.
- To highlight emerging trends in pneumonia etiology, including co-infections and viral predominance.
- To identify needs for improved prevention and management strategies.
Main Methods:
- Review of epidemiological data and vaccine impact studies.
- Analysis of trends in pneumonia etiology and clinical presentation.
- Assessment of current prevention and management strategies.
Main Results:
- Conjugate vaccines against Haemophilus influenzae type b and Streptococcus pneumoniae have significantly reduced pneumonia cases, hospitalizations, and mortality.
- Emerging evidence points to the increasing importance of co-infections and viral pathogens in childhood pneumonia.
- Disparities in access to effective interventions persist, particularly in low- and middle-income countries.
Conclusions:
- Vaccine-preventable bacterial pneumonia has declined, but viral pneumonia and co-infections present ongoing challenges.
- Enhanced access to existing preventative and management strategies is critical for low- and middle-income countries.
- Novel strategies are required to address the remaining burden of childhood pneumonia.
Abstract:
Pneumonia remains the leading cause of death in children outside the neonatal period, despite advances in prevention and management. Over the last 20 years, there has been a substantial decrease in the incidence of childhood pneumonia and pneumonia-associated mortality. New conjugate vaccines against Haemophilus influenzae type b and Streptococcus pneumoniae have contributed to decreases in radiologic, clinical and complicated pneumonia cases and have reduced hospitalization and mortality. The importance of co-infections with multiple pathogens and the predominance of viral-associated disease are emerging. Better access to effective preventative and management strategies is needed in low- and middle-income countries, while new strategies are needed to address the residual burden of disease once these have been implemented.
More Related Videos
Related Concept Videos
Pneumonia I: Introduction
Risk Factors
Various factors influence the likelihood of developing pneumonia. Age plays a crucial role, with infants, children under two, and individuals over 65 at increased risk due to their...
Pneumonia III: Complications and Assessment
Pneumonia IV: Management
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
Pneumonia II: Pathophysiology
Pneumonia V: Nursing management and Prevention
The nurse must practice strict medical asepsis and adhere to infection control guidelines to minimize healthcare-associated infections.
Enhance airway patency
Position the patient correctly to facilitate drainage of the affected lung segments. Manual or mechanical percussion and vibration can also be employed....
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

